, and the subsequent isolation of the structural protein subunits of In the years that followed, determining how gap junction channels were biosynthesized, assembled and regulated would prove to be much more complex than initially imagined. In this Timeline article, we summarize key landmarks linking gap junctions to cancer, focusing on the challenging observations that connexins display cancer type-and cancer stage-dependent functions.
The connexin family
The need to identify the gap junction genes became apparent in 1981, when the introduction of total mRNA from GJIC-competent cells was shown to be sufficient to restore GJIC in communicationdeficient cells 24 . By 1986, several independent groups had isolated cDNAs of liver gap junction proteins [25] [26] [27] and the following year the gene encoding a cardiac gap junction protein of 43 kDa was cloned and named connexin43 (Cx43) 28 . Studies in Xenopus oocytes confirmed that cDNAs encoding connexins were necessary and sufficient for GJIC 29 . Although the field continues to use the connexin prefix (Cx) followed by the predicted molecular mass of the human connexin protein in kilodaltons 14 as nomenclature, the corresponding genes were named with a GJ (gap junction) prefix followed by a letter designating the family subclass and a number indicating the cloning order within that class. For example, the gene name of human Cx43 was assigned as gap junction α1 (GJA1).
The ensuing decade of connexin gene cloning swiftly led to the realization that the connexin gene family was surprisingly large, consisting of 21 members in humans 30, 31 . Connexin antibodies, proteolysis studies and hydrophobicity analysis of the polypeptide sequences 32 revealed that all connexins consist of four transmembrane domains and two extracellular loops that are remarkably similar among connexins (FIG. 2) . The intracellular loop and C-terminal tail exhibit more divergence, with the C-terminal tail being the major determinant of connexin size, which can range from 23 to 62 kDa. It was quickly realized that connexins were expressed in every human organ, in a tissue-specific manner, and that cells almost always expressed multiple connexins 31 , gap junctions in 1974 led to their proposed naming as 'connexins' (REF. 13 ). This term later became mainstream following the cloning of the subunits towards the end of the 1980s 14 . Meanwhile, evidence began to mount suggesting that gap junctions may be causally important in tumorigenesis. Metabolic cooperation 15 , a phenomenon whereby metabolites are shared with adjoining cells, was shown to be dependent on gap junctions 16 and this was frequently dysregulated among tumour cells and between tumour cells and their normal counterparts 17, 18 . In other correlative but seminal studies, non-genotoxic chemicals often referred to as tumour promoters were shown to be effective inhibitors of gap junctional intercellular communication (GJIC) and metabolic cooperation 19, 20 . For instance, the potent tumour promoter TPA caused a rapid and significant decrease in the number of gap junctions in mouse interfollicular skin cells 21 . Not only tumour promoters, but also cancer-causing viruses, such as the avian sarcoma virus, were shown to rapidly reduce GJIC 22 . Consequently, as a putative hallmark of cancer 23 , loss of GJIC was proposed as a screening tool to identify reagents with tumour-promoting activity 19, 20 .
which can assemble into heteromeric hemichannels 33 that combine to form unique channels with specific permeability properties 34 (FIG. 2) . This diversity in channel permeability between different connexins posed a significant challenge to the field, and sorting out the transjunctional selectivity remains a daunting task.
Expression and localization
Following their cloning, it became possible to characterize connexin expression, diversity and spatial localization in tumours. These studies revealed a range of outcomes that reflect the complexity of tumour types and stages of disease 35 . Most tumours exhibited no discernible connexin expression whereas others expressed connexins in the cytoplasm or at cell-cell junctions. The elevated mRNA and protein levels of connexins that were noted in some tumours were often correlated with connexin mislocalization (for example, Cx26 (encoded by GJB2) in pancreatic 36 and colon 37 cancer, and Cx43 and Cx32 (encoded by GJB1) in prostate cancer 38 ). Similarly, recent studies tracking connexin levels as a cancer prognostic indicator produced a diverse set of outcomes. More than a dozen studies in the past decade correlate high connexin expression with a significantly better prognosis and low expression with worse prognosis (for example, Cx43 in prostate 39 , pancreatic 40 , breast 41 , head and neck SCC 42 , non-small-cell lung 43 and colorectal 44 cancers; and Cx26 in colorectal 45 and intestinal-type gastric 46 cancers). In contrast, more than a dozen studies implicating connexins in cell proliferation 59 , apoptosis 60 , chemoresistance 61 , migration 62 and invasion 63 , although not all studies point towards a tumour-suppressor role. Overexpression models also revealed that connexins regulate other features such as epithelial to mesenchymal transition (EMT), tumour cell differentiation and angiogenesis 64, 65 . To date, there are many studies on how connexins regulate molecular pathways linked to cancer biology, which are reviewed extensively elsewhere [59] [60] [61] [62] [63] 66 .
Mouse models
The mid-1990s saw the emergence of several connexin knockout (KO) mouse models (TABLE 1) . Cx32 KO mice were shown to have a significant increase in both spontaneous liver tumours 67 and chemically induced liver 68, 69 and lung tumours 70 . These findings fit well with the loss or mislocalization of Cx32 that had been previously observed in liver tumours in rats 71 and humans 72 , and the reversal of the neoplastic phenotype upon re-expression of Cx32 in rat liver cells 73 . An increase in susceptibility to chemical hepatocarcinogenesis was also observed in a transgenic mutant mouse model expressing a dominant-negative mutant (V139M) of Cx32 that causes a loss of channel function in the liver 74 . X-ray radiation also dramatically increased liver tumorigenesis in Cx32 KO mice versus wild-type mice, as well as significantly augmented tumour formation in the lung, adrenal gland, lymph nodes and small intestine with associated activation of the ERK pathway 75 . In line with this, a Cx32;p27 (encoded by cyclindependent kinase inhibitor 1B (Cdkn1b)) correlate high connexin expression with a poor prognosis (for example, Cx43 in oral SCC 47 , oesophageal SCC 48 and non-muscle invasive urothelial bladder cancer 49 and Cx26 in breast cancer 50, 51 , lung SCC 52 , oesophageal SCC 53 , colorectal cancer 37 and papillary and follicular thyroid cancer 54 ). The complexity of these mixed findings may be partly explained by the connexin family member being assessed not only in the tumour but also in the host tissue. For example, in the same breast cancer series, elevated levels of Cx43 and Cx30 (encoded by GJB6) were associated with improved and worse breast cancer outcomes, respectively 41 . In the case of Cx43, more studies favour its role as a tumour suppressor and a good prognostic indicator. Strikingly, the opposite is true for Cx26, as many more studies report its detection in tumours as a poor prognostic indicator. Thus, assessing connexin levels in human tumours is currently not a useful diagnostic method as more direct functional analysis of connexins in tumorigenesis is necessary.
Connexins as tumour suppressors
In the early 1990s, expression of specific connexins in cancer cell lines was found to be sufficient to restore GJIC and, in some cases, partially 'normalize' their phenotype. Cx43 was shown to suppress growth of transformed mouse embryo cells in vitro 55 , and to reduce rat glioma growth in vitro 56 and in vivo 57 , whereas Cx32 was shown to reduce human hepatoma cell growth only when cells were injected into mice 58 . Numerous studies followed and  substantial evidence has now accumulated   1966  1969  1972  1979  1978  1981  1986  1987  1988  1989  1990  1991  1994  1993   Tumour  cells lack  electrical  coupling   4   Tumourassociated  virus blocks  GJIC   22 Gap junctions mediate bystander effects 201, 202 Gap junctions mediate intercellular communication and metabolic cooperation 11, 15, 16 Cloning of gap junction genes [25] [26] [27] and identification of the most prevalent connexin, Cx43 (REF. 28) Gap junction proteins are phosphoproteins 112 Loss of gap junction 'nexus' plaques in tumours 9 Protooncogenes regulate GJIC 113 Expression of connexins reduces tumour growth in vitro 55, 56 and in vivo 58 Lack of metabolic coupling between tumour and normal cells 18 Identification of the first inherited connexin-linked disease 90 Connexin antibody demonstrates loss of gap junctions in tumours 252 Therapeutic potential of targeting gap junctions revealed [198] [199] [200] Oncogenes phosphorylate Cx43 Tumour promoters block GJIC and metabolic cooperation 19, 20 Milestones with direct cancer associations
Milestones with indirect cancer associations
Figure 1 | The Timeline shows key discoveries related to gap junctions and cancer. Milestones with less direct cancer associations are depicted in purple. cGAMP, 2ʹ3ʹ-cGMP-AMP; Cx, connexin; EMT, epithelial to mesenchymal transition; GJIC, gap junctional intercellular communication; mi RNAs, microRNAs.
double knockout (DKO) mouse model, displayed an increase in tumour formation in the intestine, adrenal gland and pituitary over that of the Cx32 KO, but had reduced numbers of liver tumours, pointing towards tissue-and pathway-specific interactions and crosstalk effects 76 . To complicate data interpretation further, there may also be sex-specific effects. For example, in one study a significant increase in spontaneous liver tumours was observed only in male Cx32 KO mice, whereas in female KO mice the incidence of pituitary adenoma was lower than that of control mice 67 . Although early studies suggested that connexins co-expressed within the same organ would serve similar tumoursuppressive roles, this turned out not to be the case. Unlike Cx32, conditional knockout of the other major liver connexin, Cx26, was not associated with a significant increase in the incidence of chemically induced liver tumours 77 . Yet, in a mammary gland-specific Cx26 KO mouse model, DMBA-treated KO mice developed significantly more primary and multifocal mammary tumours, compared with controls 78 , again pointing to tissue-specific effects.
Given the availability of genetically modified mice, questions arose of whether the most widely expressed connexin in mammals, Cx43, would have tumoursuppressive properties in vivo. To this end, heterozygous Gja1 +/− mice were found to be significantly more susceptible to urethane-induced 79 , DMBA-induced 80 and nicotine-derived nitrosamine ketone (NNK)-induced 81 lung tumours. Paradoxically, a correlation was noted between increased Cx43 mRNA expression specifically in the NNK-induced tumour lesions and increased tumour aggressiveness, suggesting that the tumour suppressive effect However, the advent of whole-exome sequencing of human tumours should answer the question of whether driver mutations in connexin-encoding genes can promote tumorigenesis and metastasis. Our search of the IntOGen platform 86 , which systematically analyses many sequencing projects, did not find any mutated connexin genes as a driver in any tumour type. However, from the mutational frequencies one can infer that the putative modulatory effect of connexins on cancers is likely to be connexin isoform and cancer type specific. For example, for the GJA1 gene, mutations affecting the protein sequence are more frequent in some tumours, such as stomach adenocarcinomas (2.48%, 161 samples) and cutaneous melanoma (2.44%, 369 samples), compared with the average mutation frequency of GJA1 across all tumour types (0.5%, 6,792 samples). In contrast, the GJA10 gene (which encodes Cx62) is more frequently mutated in tumours such as small-cell lung carcinomas (4.34%, 69 samples) and lung SCC (3.45%, 174 samples) compared with 0.6% mutations in all tumours (6,792 samples).
As germline and somatic mutations in nearly half of the connexin gene family have been linked to a wide range of developmental abnormalities, syndromes and diseases 87 , it should soon be possible to data-mine these patients' records for any links to cancer or disease progression. To that end, mutations in GJB2 (OMIM 121011), causing the rare syndrome of keratitis-ichthyosis deafness (OMIM 148210), appear to be associated with an increased propensity to develop skin cancer 88 . Considering that GJB2 mutations that cause the loss of Cx26-based GJIC are the most common cause of congenital sensorineural deafness (OMIM 220290) worldwide (the most common mutation, 35delG, has an estimated carrier frequency of 1 in 51 in the overall European population 89 ), the field awaits population-wide epidemiology studies to assess cancer incidence and progression in this unique population cohort. Similarly, people with X-linked Charcot-Marie-Tooth (CMTX) neuropathy (OMIM 302800), owing to mutations in the GJB1 gene 90 , will be another large group of patients to assess in detail, considering the strong links between this connexin and liver tumours in mice (TABLE 1) and, in particular, the observed tumour susceptibility of transgenic mice expressing the dominant-negative CMTX mutation V139M 74 .
is lost at late-stage lung tumorigenesis 81 . In a DMBA-induced breast cancer model, a transgenic mouse harbouring a G60S Cx43 mutant that reduces overall GJIC crossed with an Erbb2-overexpressing mouse exhibited significantly increased mammary gland dysplasia and tumour metastasis to the lungs 82 . Overall, genetically modified connexin mouse models have supported the notion that connexins are tumour suppressors. These same mouse models have also served to elucidate more complex features of tumorigenesis such as the role of connexins in the surrounding tumour microenvironment that might affect tumour growth either independently or via direct communication with tumour cells. In this respect, a recent study showed that Cx40 (encoded by Gja5) KO mice exhibited reduced angiogenesis and tumour growth of subcutaneously implanted human melanoma or mouse lung tumour cells compared with wild-type or KO mice specifically re-expressing Cx40 in endothelial cells 83 . Moreover, injecting wild-type mice with peptides that target Cx40 also reduced tumour growth 83 . This suggests that endothelial Cx40 conveys a benefit to the tumour by facilitating endothelial growth and tumour angiogenesis. Similarly, endogenous Cx43 in astrocytes appears to enhance glioma invasion in the brain through the exchange of proinvasive molecules (see below) 84 . It is clear that additional genetically modified mouse models will be needed to gain further insights into the role of connexins in tumorigenesis. First connexin knockout mouse generated 253 Pannexins discovered 240, 241 Connexin regulation in cancer Expression Although connexins have a rather simple gene structure (in most cases the entire connexin protein is encoded by a single exon), their regulation from transcription to function is under tight control and subject to a wide range of regulatory mechanisms. At the gene level, at least some members of the connexin family are subject to extensive epigenetic control 91, 92 . For example, promoter hypermethylation of GJC1 (which encodes Cx45) was shown to reduce Cx45 expression in colon cancer cell lines and in colorectal tumours 93 . At the post-transcriptional level, several microRNAs (mi RNAs) have been shown to downregulate Cx43 expression 91, 92 , for example, the miR-221/222 cluster and miR-125b in glioma 94, 95 and miR-20a in prostate cancer 96 . A less well understood aspect of gene regulation is the role of pseudogenes, ancestral copies of genes that have lost the ability to code for proteins. Some pseudogenes are transcribed and can have coding-independent functions related to tumorigenesis, as illustrated by the PTENP1 pseudogene, which competes with PTEN for miRNA binding, and as a consequence, loss of PTENP1 mRNA in tumours can lead to enhanced miRNA-mediated downregulation of PTEN protein expression 97 . This same study also identified two miR-1 binding sites in the GJA1 pseudogene GJA1P 97 . Thus, GJA1P may affect Cx43 expression its functional role is unknown 104 . Internal translation of truncated Cx43 isoforms has been shown by several groups to be strongly influenced by signalling pathways activated in cancer, including MAPK-interacting serine/threonine protein kinase 1 (MNK1; also known as MKNK1) and MNK2, AKT and mTOR 102, 105, 106 , and is also activated by hypoxia 106 , a condition linked to mTOR activation, tumour progression and drug resistance. The notion of truncated Cx43 isoforms needs to be considered in the context of non-junctional Cx43 functions (discussed below), erroneous membrane trafficking of Cx43 and accumulation of Cx43 (and its truncated isoforms) in the cytoplasm or nucleus, all aspects frequently observed in tumours 44, 47, 81, [107] [108] [109] .
Connexin gene mutations

Phosphorylation
Connexin activity is modified by many post-translational modifications, including sumoylation, S-nitrosylation, palmitoylation, phosphorylation and ubiquitylation 110 .
In the context of cancer, by far the beststudied connexin modification has been phosphorylation. It was already suggested in 1983 that cell-cell communication was regulated by protein kinase activity 111 and in 1986, phosphorylation of Cx32 was demonstrated 112 . Subsequently, loss of GJIC was shown to occur following expression of specific oncogenes, including SRC 113 and HRAS 114 , which was thought to be mediated by phosphorylation. In 1990, specific indirectly, as miR-1 is well known to inhibit Cx43 expression 92, 98 . Further investigation of the GJA1P pseudogene is clearly warranted, as reports have suggested that it is transcribed and even translated, and acts as a tumour suppressor in breast cancer cells 99, 100 . Translational regulation of connexins is also tightly controlled (reviewed in REF. 92 ) and several connexins have been suggested to possess an internal ribosome entry site (IRES) in their 5′-untranslated region, enabling maintenance of translation where cap-dependent translation may be compromised, such as in differentiated or density-inhibited cells. Notably, the antiproliferative effect of somatostatin receptor type 2 was linked to IRES-dependent induction of connexin expression causing restoration of density inhibition in pancreatic cancer cells 101 . Another recent discovery that highlights the complexity of both regulation and function of connexins is the finding that truncated isoforms of Cx43 are translated in some cell types. Smyth and Shaw 102 demonstrated internal translation of various N-terminally truncated isoforms of Cx43, with the major 20-kDa isoform acting as a chaperone protein crucial for trafficking of full-length Cx43 to the cell membrane. Interestingly, specific loss of the 20-kDa isoform (but not full-length Cx43) in human breast cancer samples has been reported, suggesting that these isoforms can be independently regulated 103 . This isoform was also described to reside in the nucleus of glioma cells, where [117] [118] [119] . Notably, TPA was shown to rapidly inhibit Cx43-mediated GJIC [120] [121] [122] , which is thought to occur through protein kinase C (PKC)-and ERK-mediated phosphorylation events 123, 124 . Cx43 is now known to be controlled by a complex network of regulatory mechanisms whereby numerous kinases and phosphatases systematically target at least 16 different phospho-sites of Cx43 (REF. 125 ). Overall, phosphorylation of Cx43 regulates its trafficking, gap junction assembly and endocytosis 126 , gap junction plaque (cluster of connexin channels) size and channel gating 127 , and degradation and protein-protein interactions 128 , ultimately either enhancing or reducing GJIC (as reviewed in REFS 125, 129, 130) . Several other connexins are phosphoproteins but much less is known about the role of kinases in regulating these other family members 130 .
Reassessing connexins in cancer
Context-dependent effects Despite extensive evidence to support connexins as tumour suppressors, many exceptions to this concept have arisen in the past couple of decades. Thus, there has been an evolution towards the understanding that in some tumours or at later tumour stages, increased connexin expression may engender tumours with more aggressive tendencies or features 66, 131 (FIG. 3) . Key evidence for this concept emerged in 2000, when mouse melanoma cells transfected with cDNA coding for Cx26 were shown to display increased metastatic potential when injected subcutaneously into mice 132 . The authors suggested that this was due to enhanced intravasation and extravasation, as Cx26 facilitated heterologous GJIC between melanoma cells and endothelial cells in ex vivo assays. Several other studies now suggest that increased connexin expression within the tumour (and even in the tumour stroma 133 ) at late-stage disease facilitates metastatic features such as migration and invasion [134] [135] [136] [137] (reviewed in REF. 63 ), endothelial adhesion 138, 139 , intravasation and extravasation 132, [139] [140] [141] [142] [143] , and targeting to the metastatic site 144 . In addition, a recent study clearly demonstrates how Cx43 can increase the growth of brain metastases at a very late stage, after extravasation and remodelling of existing vascular networks 145 . Some of these features may be isoformspecific effects. For example, Cx43 expression reversed EMT and prevented resistance to cisplatin chemotherapy in the A549 lung Cx26, and not Cx32 or Cx43, was shown to repress tumorigenic features in HeLa cervical cancer cells, even though all three connexins enhanced GJIC 150 . A more recent study 151 has provided insight into a potential isoform-specific GJIC-dependent molecular mechanism behind these observations, whereby Cx26, but not Cx32 or Cx43, maintains functional GJIC during the G2/M phase, which favours intercellular redistribution of cAMP, delaying cell cycle progression. However, it is also clear that specific GJIC-independent mechanisms operate (see reviews REFS 59, 152) for which two different functional explanations have gained popularity: first, connexin hemichannels communicating with the extracellular environment and second, the role of connexin-interacting proteins.
Hemichannels. Evidence has emerged that unpaired gap junction channels otherwise known as connexin hemichannels act as direct channels between the cell cytosol and the extracellular milieu 153 (FIG. 2) . ATP release and modulation of Ca 2+ concentrations regulate cell proliferation in several cell types [154] [155] [156] , and inappropriate hemichannel opening may underlie some hyperproliferative disorders such as hidrotic ectodermal dysplasia 157 . Hemichannel functions have also been linked to vascular disruption and haemorrhage within tumours 158 , and recently Cx43 hemichannels of osteocytes have been found to be involved in suppression of breast cancer cell growth and bone metastasis 159 . adenocarcinoma cell line 146 , whereas Cx26 expression induced EMT via the PI3K-AKT signalling pathway and conferred resistance to the epidermal growth factor receptor (EGFR) inhibitor gefitinib in HCC827 and PC9 lung adenocarcinoma cells 147 . Similarly, tissue-specific effects also need to be considered: although Cx26 promotes EMT in lung cancer cells 147 , it was shown to reverse EMT-like features in breast cancer cells 64 . 148 . In support of this notion a recent study showed that, although restoration of Cx30 expression reduced growth of glioblastoma cell lines, it indeed conferred resistance to γ-radiation 149 . Furthermore, in cohorts of patients treated with radiation therapy, expression of Cx30 was associated with increased mortality 149 . Taken as a whole, stratification of tumour subtype, stage and heterogeneity with connexin isoform profiles should be carried out to delineate connexin function in cancer.
Non-junctional functions
Increasing evidence suggests that connexins also have functions unrelated to GJIC that are important in cancer progression. This idea arose from the observation that only However, the link between hemichannels and cancer is difficult to establish conclusively, as most reagents that block gap junction channels also block connexin hemichannels, making assignment of functional consequences specifically to hemichannel functions problematic 160 . Furthermore, studies may also be confounded by the action of pannexin channels that also enable communication between the cellular cytosol and extracellular milieu
Connexin-interacting proteins. Connexin hemichannels alone are not sufficient to explain studies in which connexins retained in the Cx43 interactome. Although all connexins probably interact with at least a few proteins, the Cx43 interactome is extensive (FIG. 4; Supplementary Information S1 (figure), S2 (table)). Notably, Cx43 is known to bind directly to many key cancer-regulatory proteins, including caveolin 1 (REF. 164 ), nephroblastoma overexpressed (NOV, also known as CCN3) 165, 166 , discs large homologue 1 (DLG1) 167 , SRC 168 and BCL-2-associated X protein (BAX) 169 . Some of the functional consequences are being elucidated in more detail. For example, Cx43 can regulate cellular migration via an interaction in intracellular compartments regulate cellular characteristics associated with cancer. Indeed, the ectopic expression of a C-terminal tail fragment of Cx43 alone was as efficient as full-length Cx43 in inhibiting the proliferation of the mouse neuroblast cell line Neuro2a 161 . This finding was supported by similar observations in human osteosarcoma U2OS cells and immortalized monkey COS-7 cells 162 . Cell growth was also reduced in non-tumorigenic cardiomyocytes, where the C terminus of Cx43 was reported to be localized to the nucleus 163 . The mechanistic explanation for these observations is probably rooted Nature Reviews | Cancer f | Once at the metastatic site, the roles of connexins are less clear, with some evidence for connexins promoting tumour cell dormancy but also promoting survival in that context. g | Some evidence suggests that connexins reduce cell growth directly in metastases, but at the same time may stimulate local invasion and survival. h | Therapy response, which includes chemoresistance, can be achieved via multicellular connections between cancer cells or between cancer cells and healthy cells and may be connexin isoform specific (green and purple tumour cells indicate establishment of new clones). Moreover, this process will be highly influenced by the specific microenvironment and whether the overall exchange of signals promotes the 'kiss of life' or 'kiss of death'
. Dark purple boxes indicate overall connexin effect and light purple boxes denote the specific stage in cancer progression at which connexins function. ECM, extracellular matrix.
with calcium/calmodulin-dependent serine protein kinase (CASK; also known as LIN2) 170 , but it is also clear that this and other Cx43 interactions occur through complex protein networks, as reviewed elsewhere 171 . Interactions between Cx43 and other proteins, such as zona occludens 1 (ZO1) 172 , are also of importance for Cx43 channel assembly and regulation specifically during cancer progression. Apart from direct and indirect Cx43 interactions, Cx43 may change the expression levels of other proteins important in cancer, such as Cx43-mediated downregulation of p27 via E3 ubiquitin ligase complexes containing S-phase kinase-associated protein 2 (SKP2) 173 . Reports in recent years have noted that connexins may take up residence in unexpected intracellular compartments. Notably, Cx43 was detected in the inner membrane of the mitochondria of cardiomyocytes 174 , possibly regulating cytochrome C-mediated apoptosis 175 , raising the idea that mitochondrial Cx43 may also have a role in cancer. In pancreatic tumour cells, Cx43 was shown to induce apoptosis through an interaction with the mitochondrial anti-apoptotic protein BAX 169 . Moreover, in a human glioblastoma cell line, Cx43 enhanced the efficacy of several chemotherapy agents via downregulation of anti-apoptotic BCL-2 in a GJIC-independent manner 176 . However, this is contrasted by recent studies in which the BAX-BCL-2 pathway was also shown to be regulated by Cx43 in human glioma cell lines, but in this case, Cx43 seemed to increase resistance to temozolomide chemotherapy, via both GJIC-dependent and GJIC-independent pathways 177 . Cx43 downregulation was also shown to affect the cytoprotective properties of tumour cells by causing enhanced sensitivity and mitochondria-mediated apoptosis in response to low-dose γ-radiation 178 . Mitochondrial translocation of Cx30 also seems to provide resistance to γ-radiation in human glioblastoma cells 149 . Additional studies are needed to determine whether targeting the mitochondria-connexin relationship would have any putative therapeutic potential.
Novel connexin functions
The complexity of cancer progression is underscored by the continual identification of new pathways, concepts and features that regulate tumour onset and progression, many of which exhibit some level of crosstalk with connexins.
have different functions in CSCs versus non-CSCs, a significant reappraisal of their role in cancer is needed. Towards this end, the use of more accurate or representative CSC systems would be required, such as the emerging use of patient-derived xenograft (PDX) models 183 . Related to this, breast cancer PDX mice were recently used to study features of circulating tumour cells (CTCs), in which the authors identified a signature of four genes that included downregulated GJA1 and was associated with both CTCs and lung metastasis 184 . Indeed, this four-gene profile predicted a reduction in distant metastasis-free survival in patients with early breast cancer 184 . Taking into account the rising importance of CSCs and CTCs in understanding metastasis, tumour cell response to treatment and disease recurrence, these models may assist the gap junction field in understanding some of the apparently contradictory results documented over the past 50 years. miRNA transfer. Gap junction-mediated transfer of mi RNAs is an emerging field that might help resolve some aspects of the connexin-carcinogenesis link. Lim et al. 185 investigated tumour dormancy in bone marrow metastasis and suggested that gap junction-mediated transfer of C-X-C motif Cancer stem cells. As the concept and importance of cancer stem cells (CSCs) emerged, so did the hypothesis that these cells, like tumour cells, were uncoupled or had a distinct connexin expression profile. Indeed, more than a decade ago, loss of GJIC in CSCs was suggested as a potential hallmark of cancer 179 (FIG. 3) .
Some studies have supported this premise; notably, nestin + /CD133
+ glioma CSCs were shown to have low levels of Cx43 expression and reduced GJIC 180 . Moreover, Cx43 expression in these CSCs inhibited growth, tumour-sphere self-renewal and invasion in vitro, as well as tumorigenicity in mouse xenografts 180 . In contrast, Cx32 was localized to the cytoplasm and was suggested to enhance the CSC self-renewal in Huh7 hepatoma cells 181 , raising the question of whether connexin isoform specificity is crucial. Intriguingly, glioblastoma CSCs were shown to express Cx46 whereas non-CSCs expressed Cx43 (REF. 182 ), suggesting that specific channel permeability properties regulate self-renewal versus differentiation. This result also has implications for the therapeutic concept of the 'bystander effect' , whereby spread of either death or survival signals between neighbouring cells may occur via functional GJIC as discussed in detail below. If connexins truly
Box 1 | Pannexins: communication in another language
Pannexins (a family of three members: pannexin 1 (PANX1), PANX2 and PANX3) were identified in 2000 on the basis of sequence homology to the invertebrate gap junction proteins, the innexins, and were quickly proposed to be a new family of ubiquitously expressed vertebrate gap junction proteins 240, 241 . Even though they have no sequence homology to connexins, they exhibit comparable topology, with four hydrophobic transmembrane domains, three cytoplasmic domains, including the N-and C-terminal tails and two extracellular loops. Early studies suggested that they may form intercellular channels 241 . However, it is now clear that their main function is to make cell surface single-membrane channels that release autocrine and paracrine signals to the extracellular matrix 242 , analogous to the proposed functions of connexin hemichannels (FIG. 2) . Similar to what was described for connexin43 (Cx43) more than two decades earlier 56 , the overexpression of PANX1 (REF. 243) or PANX2 (REF. 244 ) in rat C6 glioma cells reduced monolayer cell growth and in vivo tumour growth in immunocompromised mice. In untransformed cells, such as rat epidermal keratinocytes, PANX1 and PANX3 also reduced cell growth when overexpressed 245 . Likewise, in chondrocytes, PANX3 promoted a switch from proliferation to differentiation 246 , and recently, PANX3 was shown to significantly inhibit osteoprogenitor cell growth through inhibition of the WNT pathway and via calcium-mediated regulation of cyclin-dependent kinase inhibitor 1A (CDKN1A, which encodes p21) 247 . As with connexins however, pannexins may also possess pro-tumorigenic features. PANX1 overexpression induced neural progenitor cell proliferation, possibly via ATP release 248 , and knockdown of PANX1 in mouse melanoma cells induced cell re-differentiation and reduced tumour growth 249 . A recent elegant study 250 identified PANX1-mediated ATP release as a mechanism of metastatic cell survival in the microvasculature, and channel inhibition significantly reduced breast cancer metastasis. Another relevant finding is the link between PANX1, cell death and the release of 'find-me' ATP and ADP signalling molecules that activate the immune system 251 . Finally, it is important to note that many of the pharmacological agents used today block both pannexin and connexin channels, and both channel types have been well documented as forming separate large-pore channels that engage in ATP release. Identification of isotype and disease stage specificity is needed to clearly discern the functional role of these two families of channel-forming proteins in cancer.
chemokine ligand 12 (CXCL12; also known as SDF1)-specific mi RNAs between bone marrow stroma and breast cancer cells maintained cancer cell quiescence. Conceptually, co-culture experiments had already demonstrated gap junctionmediated miRNA transfer between miR-67-overexpressing and miR-67-negative glioma cells, a process blocked by the GJIC inhibitor carbenoxolone 186 . More recently, miRNA transfer from glioma cells to astrocytes was shown to enhance the glioma pro-invasive potential 133 . In contrast, gap junction-mediated miRNA transfer between miR-124-3p-transfected and non-transfected glioma cells had anti-proliferative effects, demonstrating a miRNA-mediated bystander effect 187 . Subsequently, it was suggested that several mi RNAs associated with survival and can facilitate the release of exosomal content into target cells 190 , an exciting finding that needs to be further addressed.
Gap junctions in immune cells.
Gap junctions are known to regulate (and to be regulated by) inflammatory responses such as cytokine release and, surprisingly, connexins are now known to be widely expressed in immune cells, as reviewed in REF. 191 . This line of investigation gained further interest following the 2005 report of cross-presentation of possible antigens via gap junction-mediated direct transfer of small peptides (of up to 10 amino acids in length if unstructured) 192 , a feature that may be lost as tumours shut down GJIC. In cancer, Cx43-derived gap junctions seem to participate in melanoma antigen transfer and cross-presentation between human dendritic cells (DCs), potentially facilitating a more effective DC-mediated T cell activation 193 .
Another study suggested that activation of autophagy in hypoxic melanoma cells selectively causes degradation of gap-junctional Cx43, potentially impairing natural killer cell-mediated tumour cell killing 194 . In addition to peptides, gap junction-mediated transfer of mi RNAs from macrophages to hepatocellular carcinoma cell lines has been reported to regulate gene expression and inhibit tumour cell proliferation 195 . The physiological role of GJIC-mediated miRNA and peptide transfer in immune cells remains poorly defined, but, considering the recent promising advances in cancer immunotherapy, the idea of potentiating the antitumour immune response through modulation of GJIC deserves further attention. Towards this end, induction of Cx43 expression caused by infection of melanoma cells with bacteria enabled transfer of preprocessed tumour antigens from melanoma cells to DCs, improving DC-based tumour vaccination by increasing T cell activation and antitumour immunity 196 .
Multicellular interconnections.
Tumours develop and grow in a complex microenvironment that contains both diseased and normal cells. Several recent studies suggest that GJIC between tumour cells and normal cells may be detrimental to the host, for example, by facilitating metastasis and host colonization 132, 142 or by enhancing the local brain invasion, as seen in gliomas 84 . Another recent study suggests that gap junction-mediated diffusion of pro-survival short RNAs between mouse astrocytes and human tumour cells provides increased chemotherapy resistance passed through gap junctions formed between astrocytes and lung tumour cells in vitro 188 . The discovery that mi RNAs transfer through gap junctions thus requires substantial reassessment of which intercellular signals are important in regulating carcinogenesis. There is a strong possibility that different tissues and cells express mi RNAs with both positive and negative effects on growth
, and it is likely that miRNA permeability will differ depending on the connexin isoforms expressed 189 . Lim et al. 185 noted that miRNA transfer occurred not only via gap junctions but also by delivery from exosomes (secreted double-membrane structures that can carry proteins, lipids, mi RNAs and mRNAs, which probably regulate cancer progression). Cx43 has now been shown to exist as hexameric channels in the membrane of exosomes and Nature Reviews | Cancer The network was retrieved and constructed using the STRING database version 10.0, using the most stringent confidence score prediction setting (>0.9), resulting in 28 interactions. An extended interaction network (high confidence prediction, >0.7, 99 interactions) can be viewed in Supplementary information S1 (figure). Full names, score prediction and details of specific proteins are available in Supplementary information S2 (table). resistance to chemotherapy 188 . Connexins have now been linked to yet another feature related to multicellular interconnectionsOsswald et al. 197 reported that astrocytoma cells were connected by microtubes that facilitate invasion and resistance to radiotherapy. These microtubes were shown to contain Cx43 that could facilitate the spread of toxic levels of calcium following radiation therapy. Consistent with a long-standing concept in the gap junction field, these authors suggest that intercellular microtubes enable individual tumour cells to promote cell survival by diluting out lethal levels of calcium or other toxic metabolites 197 
. Whether networks of microtubes exist in other cancer types, and what their prognostic and therapeutic value is, are important future questions. Related to this, a recently described carcinomaastrocyte interaction network was shown to promote brain metastasis of breast and lung cancers 145 . In this study, Chen et al. showed that double-stranded DNA could induce the production of the second messenger 2ʹ3ʹ-cGMP-AMP (cGAMP) in tumour cells, which upon traversing to astrocytes via Cx43 gap junctions, activated the stimulator of interferon genes (STING) pathway. Subsequently STING mediates production of interferon-α (IFNα) and tumour necrosis factor (TNF) in astrocytes, which in turn act as paracrine signals to stimulate signal transducer and activator of transcription 1 (STAT1) and nuclear factor-κB (NF-κB) survival pathways in the neighbouring cancer cells 145 . 199, 200 2 years later demonstrated the therapeutic that gap junctions promoted the bystander effect and enhanced ganciclovir therapy 206 . Several articles substantiated the role of GJIC in the bystander effect [207] [208] [209] [210] [211] , including very recent studies in breast cancer 212 , although some studies reported little or no effect 213 . Conversely, it was proposed 214 that HSV-TK-transduced cells could be significantly protected from cell death by neighbouring cells via GJIC, possibly through the dilution of ganciclovir (or activated ganciclovir) or by the sharing of survival signals (the so-called 'Good Samaritan effect'). Thus, whether actively enhancing GJIC would increase or decrease drug killing of tumour cells is not well defined 214 . The 'kiss of death' or 'kiss of life' conundrum (BOX 2) may be linked to the concentration of the effector, the connexin isoforms 215 and whether connexin-independent mechanisms are involved 213, 216 .
Regulating connexin function
Several natural compounds have been shown to upregulate GJIC and potentially modulate cancer growth or enhance cytotoxic therapy; examples include retinoids and carotenoids 61, 198, 199, [217] [218] [219] [220] , various flavonoid antioxidants such as genistein, quercetin, green tea catechins and caffeic acid phenethyl ester [221] [222] [223] [224] [225] [226] [227] and other non-flavonoid chemicals such as sulforaphane and red wine resveratrol 228, 229 . However, these upregulating approaches are not connexin or GJIC specific. In a more promising and direct approach, a phase II trial has begun in which a peptide mimetic is being used to increase Cx43-based GJIC (but reduce hemichannel activity) as a potential treatment for chronic wounds 230 . In cancer, it would be crucial to use peptide mimetics potential of targeting GJIC using two independent approaches. First, they provided further evidence that adding chemicals such as dibutyryl cAMP, fluocinolone acetonide or dexamethasone could be used to re-establish communication between transformed cells and normal neighbouring cells, leading to inhibition of cell transformation and potentially also causing transformed cells to revert to a normal phenotype 199 . Second, they took advantage of the specific lack of heterologous gap junction communication between GJIC-competent transformed and non-transformed cells by injecting Lucifer Yellow (LY) dye so it would spread only between transformed cells 200 . Subsequent blue light irradiation (which activates LY) specifically killed the tumour cells that had received LY via GJIC 200 .
Bystander effect
The work of Yamasaki and Katoh 199, 200 was followed by a period in the 1990s when studies suggested that GJIC and connexins could underlie the bystander effect observed during suicide gene therapy approaches, a concept stemming from the demonstration of GJIC-mediated metabolic cooperation 15, 16 . Using the herpes virus thymidine kinase (HSV-TK) gene to render cancer cells sensitive to the drug ganciclovir, it was noted that HSV-TK-free neighbouring cells also died. In vitro studies indicated that a metabolite by-product of ganciclovir passed to uninfected cells via gap junctions, causing cell death 201, 202 , and the extent of this bystander cytotoxicity was shown to correlate with GJIC activity 203 . Expression of connexins and the subsequent levels of GJIC correlated well with the bystander effect in vitro 204, 205 . In vivo studies also suggested An unresolved issue, partly owing to its enormous complexity, is the full elucidation of the exact signalling molecules exchanged via gap junctional intercellular communication (GJIC) that modulate cancer malignancy. Gap junction-permeable signals known to be important include calcium, ATP, cAMP, cGMP, 2ʹ3ʹ-cGMP-AMP (cGAMP), polyamines, nucleotides, glutathione, amino acids (such as glutamate) and other nutrients such as glucose. However, the Human Metabolome Database (HMDB) currently lists 39,674 metabolites smaller than 1,500 Daltons (thus potentially small enough to diffuse through gap junction channels). In addition, an increasing number of reports suggest that microRNAs [185] [186] [187] [188] [189] and potentially even small peptides 192, 193, 196 can pass through gap junctions (FIG. 2) .
Depending on the specific signalling molecule exchanged through a gap junction channel, whether between tumour cells or between tumour cells and normal cells, it may provide either an advantage or a disadvantage to the target cell. This conundrum was first evident in the ganciclovir cancer therapy field and the associated 'bystander effect', whereby a possible dual-effect or kiss of death and kiss of life scenario was depicted 215 . The advantages of keeping rather than sharing metabolites probably depend on the specific signal, its concentration and, perhaps, the stage of the tumour. Altogether these variables would influence the balance of positive and negative growth of the tumour. In this sense, the specific channel permeability properties of various connexin isoforms may also dictate how these connexins affect tumour growth differentially.
that either enhance GJIC in early-stage disease when it may suppress tumour growth or block connexin functions in late-stage disease when the connexin seems to give the tumour a survival advantage. However, using peptides to target connexins has not yet been endorsed for clinical trials in cancer treatment.
Since the early discovery of the reversible chemical inhibitor of GJIC 18-α-glycy r rhetinic acid 231 , technological advances have brought several additional modalities (for example, epigenetic modulators, antibodies, peptides, antisense RNA, mi RNAs and CRISPRCas9) to inhibit GJIC and connexin functions. The long-standing hypothesis that connexins are tumour suppressors would argue against GJIC inhibition in a cancer treatment setting, particularly when treating primary tumours that have not yet metastasized. However, this position must be readdressed given the growing evidence that connexins facilitate metastatic disease in some specific cases. Indeed, the GJIC blocker oleamide was recently found to have antimetastatic properties in MDA-MB-231 breast cancer cells in vitro, and in vivo following intravenous delivery in mice 143 . From a therapeutic point of view, very promising and potent effects were recently reported in the aforementioned work of Chen and colleagues 145 . Blocking heterologous breast and lung carcinomaastrocyte gap junctions, either using gap junction inhibitors (tonabersat or meclofenamate) that pass the blood-brain barrier or by Cx43 knockdown, clearly prevented metastasis progression in mouse models. Moreover, combining this treatment with traditional chemotherapeutics (carboplatin) was highly effective at blocking metastasis 145 . In addition to pharmacological approaches to regulate GJIC, Cx43 blocking antibodies have also been shown to reduce tumour growth either alone 232 or in combination with standard cancer therapy 233 . In other novel cases, Cx43 antibodies have been used as a guidance system to deliver diagnostic markers or therapeutic compounds such as cisplatin to Cx43-positive tumour cells 234, 235 . Another strategy that has potential promise in cancer therapy is the use of short connexin mimetic peptides to modulate connexin function or gap junction permeability, although these have mostly been applied to treating inflammatory diseases 236 . For instance, a peptide (αCT1) mimicking the C terminus of Cx43, blocking the interaction of ZO1 cannot dismiss the importance of connexins in protecting against tumour onset and early disease progression, as prevention is arguably more important than treatment. The success of translational efforts will clearly rely on the continual elucidation of the complex biological regulation and function of connexins. We predict that any useful treatments that emerge will take tumour type, tumour stage and tumour properties into account. It also seems clear that targeting connexins alone is not likely to be enough, and combinatory treatments will be necessary. Future efforts to move this field forward will require multifaceted approaches to elucidate fundamental aspects such as the role of connexins in CSCs, non-junctional functions, and to fully appreciate their role system-wide, such as in the immune system or in tumour stroma. Our current understanding of half a century's worth of research on gap junctions and cancer can potentially be used to develop effective therapeutics of benefit to cancer patients.
with Cx43, was shown to cause specific inhibition of Cx43 hemichannel function (although maintaining GJIC), which prevented temozolomide resistance in human glioblastoma cell lines 237 . In another study, the same peptide augmented the effect of the oestrogen receptor modulator tamoxifen and the ERBB2 inhibitor lapatinib in breast cancer cell lines, although the authors suggested that the key function of the peptide in this setting was to enhance GJIC 238 . The exact mode of action of this peptide seems complex and perhaps even context dependent.
Nevertheless, these exciting new therapeutic developments provide hope for the development of novel anticancer drugs targeting connexins for the treatment of specific tumours. Although connexins are attractive therapeutic targets owing to their exposure on the cell surface and the ability of drugs to block channel activity, there are significant challenges, as connexins are also crucial for healthy tissue function. Targeting (GJIC-independent) cancer-associated connexin-protein interactions may be one approach towards reducing possible side effects associated with loss of essential GJIC functions (for example, electrical coupling in heart or brain). Using this strategy, a cell-penetrating peptide that mimicked and blocked the Cx43 binding site of SRC induced differentiation of glioma stem cells, providing a proof-of-principle that this approach has merit 239 .
Concluding remarks
As personalized medicine continues to advance and focus on patient-specific global gene expression profiles, the analysis of how gap junctions contribute to the physiology and pathology of patient-specific tumours will be highly informative. The connexin isoforms expressed, the tumour type or subtype and the stage of disease significantly influence the role of connexins in tumours. In this context, both channel-dependent and -independent functions are likely to operate, in a complex interplay between the tumour cells and the surrounding micro environment. The breadth of studies linking connexins to cancer is daunting and an overall generic message has not emerged that can be applied to all tumour types. In fact, it is perhaps ironic that some of the apparently successful connexin-based anticancer treatment modalities reported in the past few years are based on blocking connexin and gap junction activity in advanced disease, a concept inconsistent with the mainstream beliefs of the field over the past 50 years. However, we
